New program combines IV-delivered TRACER capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager's wholly- ...

Synendos Therapeutics appoints Dr. George Garibaldi to move phase 2 clinical development of its lead drug asset SYT-510: Basel, Switzerland Wednesday, July 16, 2025, 15:45 Hrs [IS ...

Treatment with memantine in a small cohort of individuals with post-traumatic headache led to fewer average headache days per ...

Scientists challenging conventional beliefs around the genetic risk factors for Alzheimer’s have discovered a genetic link ...

Overview of Autologous Cell Therapy Product MarketGlobal Cell Therapy Market is valued at USD 10.1 Billion in 2025 and is ...

Synendos Therapeutics (“Synendos”), the clinical-stage biotechnology company developing breakthrough therapies for ...

With clinical trials under pressure, industry leaders say it’s time for reform, digital transformation, and more patient-centric models.

As Alzheimer's disease progresses beyond the early stages, the behavior changes and emotional impacts of the disease can be ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...

The value of a recent biochemical discovery can be seen in the case of an 8-year-old boy, who was playing typical sports in ...

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect product line for assessing symptomatic ...